Nvidia, Eli Lilly to Launch AI-Powered Co-Innovation Lab
By Elias Schisgall
Nvidia and Eli Lilly are partnering to launch a co-innovation lab to use Nvidia's artificial-intelligence and robotics expertise for drug discovery.
The companies said Monday they would invest up to $1 billion in talent, infrastructure, and computing power, including Nvidia's Vera Rubin chips, over the next five years. They said the new lab would expand the buildout of Lilly's Nvidia DGX SuperPOD and AI factory.
"We see this as a catalyst for the capabilities that will define the next era of drug discovery," Lilly Chief Information and Digital Officer Diogo Rau said. "We're moving toward a future where discovery is driven by rapid experimentation and increasingly customized models -- an approach that reflects our commitment to leading applied AI in drug discovery and investing deeply in new forms of data generation and model development."
Nvidia also said it was collaborating with Thermo Fisher to automate the company's research labs and data analysis.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
January 12, 2026 10:34 ET (15:34 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
United States